.jpg)
.png)
All
The ODYSSEY OUTCOMES trial results, announced today at the American College of Cardiology 67th Annual Scientific Sessions in Orlando, revealed the addition of alirocumab to maximally tolerated statin significantly reduced major adverse cardiovascular events (MACE) compared to those on maximally... more
Adults Older than 75 Years without ASCVD Infographic Manuscript Apolipoprotein B Infographic Manuscript Familial Chylomicronemia Syndrome Podcast Manuscript Familial Hypercholesterolemia Manuscript Lipoprotein(a) Infographic Manuscript... more
I have a 6 yo M seen in consultation recently for elevated LFTs, found on routine labs by PMD, AST/ALT 68/111, rest of chem 20 normal. TC 75, TG 127, HDL 13, LDL 37, TFTs normal, CBC shows slightly low Hb at 10.6. Asymptomatic, no signs on physical exam including no HSM, eating and growing well,... more
Join the Association of Black Cardiologists for a Dinner Meeting on Saturday, November 16 in Dallas, TX. Joel Buxbaum, MD and Jared Gollob, MD will talk about ‘New Frontiers in Cardiac Amylodosis: Epidemiology, Diagnosis and Treatment Aspects.’ For more information and registration,... more
The Lenox Hill Hospital Preventive Cardiology fellowship will offer candidates the opportunity to become adept in the clinical and research components of preventive cardiology. The main areas of focus will include utilization of advanced medical therapies for the treatment of complex... more
The National Lipid Association is excited to announce a month-long extravaganza of virtual education, LipidPALOOZA, launching this September to celebrate National Cholesterol Education Month. There will be a variety of activities spread throughout the entire month and best of all, they will be... more
Amit Khera, M.D., Saskia Neher, Ph.D., each earn two-year grant for lipid disorder research NLA Junior Faculty Research Award Information JACKSONVILLE, Fla. — The National Lipid Association (NLA) announced on Thursday the recipients of its inaugural Junior Faculty Research Awards for... more
One of the NLA's missions is to move our educational efforts towards practicing based on best evidence. You will be seeing segments of Lipid Spin dedicated to this objective. There are many interesting aspects of lipidology addressed and displayed in a multi-disciplinary fashion in this edition... more
Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD). Although approximately 20% of the population has elevated Lp(a) levels (≥ 50 mg/dL or 125 nmol/L), there are currently no approved targeted medical treatments available. Lp(a) has a unique... more
Discuss this article at www.lipid.org/lipidspin Diabetes mellitus (DM) is a leading cause of cardiovascular disease (CVD) and its associated morbidity and mortality.(1) DM confers the highest lifetime risk of any individual risk factor for developing cardiovascular disease. Although morbidity... more